



GLAND PHARMA LIMITED

April 12, 2021

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol : GLAND (ISIN : INE068V01023)

Dear Sir/Madam,

Sub: Earnings Conference Call

In continuation to our intimation dated April 3, 2021, regarding the Board Meeting Notice, please find enclosed details of the Earnings Call for Investors/Analysts to be held on **Monday, 17th May, 2021 at 1830 - 1930 hours IST.**

The transcript of the Earnings Call will be available on the Company's website.

This is for your information and records.

Yours truly,

For Gland Pharma Limited



Sampath Kumar Pallerlamudi
Company Secretary

Encl.: as above



Announcement

EARNINGS CONFERENCE CALL

The Company will host an Earnings conference call on May 17th 2021, at 18:30 hours (IST), during which the leadership team will discuss the financial performance and take questions. Audio record and Transcript of the conference call will be available at www.glandpharma.com.

Earnings Conference Call Dial-in Information

Date and Time	May 17, 2021 at 18:30 – 19:30 hrs. (IST)
Dial-in Numbers	
Universal Dial-in	+91 22 6280 1516 / +91 22 7115 8875
Diamond pass link	Click here to register
National Toll Free	1 800 120 1221 / 1 800 266 1221
International Toll Number	USA: + 1 3233868721 UK: + 44 2034785524 Hong Kong: + 852 30186877 Singapore: + 65 31575746

Playback of Earnings Conference Call audio:

Playback of the earnings call will be available after the end of the call in the below mentioned numbers:

Dial-in Numbers	Access code	Replay Dates
India (+91 22 71945757) Hong Kong (800965553) Singapore (8001012510) UK (8007563427) USA (18332898317)	91582#	May 17 th till May 24 th 2021

Contact:

Investor Relations

Sumanta Bajpayee

Vice President – Investor Relations

E- Mail: sumanta.bajpayee@glandpharma.com and investors@glandpharma.com